To hear about similar clinical trials, please enter your email below
Trial Title:
Evaluation of CG-100 Intraluminal Bypass Device
NCT ID:
NCT05632744
Condition:
Colorectal Cancer
Conditions: Official terms:
Colorectal Neoplasms
Study type:
Interventional
Study phase:
N/A
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Device
Intervention name:
CG-100 Intraluminal Bypass Device
Description:
Subjects will be treated with the CG-100 Intraluminal Bypass Device
Arm group label:
CG-100 Intraluminal Bypass Device
Summary:
Evaluation of CG-100 Intraluminal Bypass device
Criteria for eligibility:
Criteria:
Inclusion Criteria (pre-operative):
1. Willing to comply with protocol-specified follow-up evaluations
2. 22-75 (inclusive) years of age at screening
3. Diagnosed with colorectal cancer
4. Has been informed of the nature of the study, agrees to its provisions, and has
provided written informed consent
Gender:
All
Minimum age:
22 Years
Maximum age:
75 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Soroka Medical Center
Address:
City:
Reẖovot
Country:
Israel
Status:
Recruiting
Contact:
Last name:
Ilia Pinsk
Email:
iliapi@clalit.org.il
Start date:
March 15, 2023
Completion date:
June 15, 2024
Lead sponsor:
Agency:
Colospan Ltd.
Agency class:
Industry
Source:
Colospan Ltd.
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05632744
